This suggests that passive immunization with tau antibodies is usually a viable therapeutic goal and the CSF amount of p-tau262/356 or on the microtubule binding domain (MTBD) can function a handy biomarker of tau pathology to watch tau therapeutics in clinical trials.They shown this partnership with equally pathological specimens and by tau PET, p